Grapy CEO presents evidence-based medical innovation strategy at Korea 3D Printing Convergence Medical Society conference

Grapy CEO Shim Un-seop delivered a special lecture at the 14th Annual Conference of the Korea 3D Printing Convergence Medical Society, held May 15, 2026 at Seoul National University Global Engineering Education Center. In his presentation titled 'Where Evidence-Based Research Meets Medical Innovation,' Shim argued that the medical 3D printing industry must evolve beyond simple manufacturing and output services into a trust-based industry grounded in clinical evidence, data accumulation, standardization, and regulatory response. He diagnosed that many companies remain stuck in a 'tool industry' phase focused on equipment sales and printing services, while Grapy is pursuing an integrated system strategy centered on its Shape Memory Aligner (SMA) clear aligner product, encompassing material, process, standard operating procedures, clinical data, and user training.

This presentation lands squarely within the medical-dental vertical's ongoing transition from prototyping to regulated production. Grapy's emphasis on evidence-based research and standardization reflects the structural reality that medical device AM requires long-term clinical data accumulation and regulatory qualification — a pattern familiar from the aerospace qualification grind but compressed into the faster-paced dental market. The company's SMA clear aligner positions it against Align Technology's massive VPP-based production operation, but Grapy is differentiating through a shape-memory material approach rather than conventional thermoforming. Shim's call for transparent, standardized ecosystems involving industry, academia, research institutes, and government signals recognition that no single company can build the regulatory infrastructure alone.

For Grapy, the practical challenge is translating this strategic framing into published clinical data and regulatory clearances that can compete with Align's entrenched position. The company's integrated system approach is sensible but execution-dependent — the medical device market rewards evidence, not architecture diagrams. Buyers in the dental AM space should watch for peer-reviewed outcomes and regulatory milestones rather than strategic positioning statements.